News

BioNTech SE and Shanghai Fosun Pharmaceutical jointly announced that their lead mRNA COVID-19 vaccine candidate BNT162b2 will be evaluated in a Phase 2 clinical trial in Taizhou and…
Read More...

Therapeutics Solution International, Inc., reported clinical trial data demonstrating significant increases in natural killer cell activity in 12 healthy volunteers receiving daily…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) as a treatment to prevent…
Read More...

Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, announced that the first patient has…
Read More...

CureVac N.V. a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Wacker Chemie AG announced that they had…
Read More...

Pfizer Inc. announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being…
Read More...

GlaxoSmithKline plc announced that patient dosing has begun in a phase 3 clinical programme investigating the safety and efficacy of its Respiratory Syncytial Virus (RSV) candidate…
Read More...

Merck, known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, announced that the companies have entered into a…
Read More...

Syngene International and Deerfield Discovery and Development Corporation (3DC), the drug discovery and development subsidiary of Deerfield Management Company (Deerfield), have signed…
Read More...

Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Lonza announced a strategic partnership to…
Read More...

Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the…
Read More...

RedHill Biopharma Ltd. a specialty biopharmaceutical company, today announced that it has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a potential…
Read More...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage…
Read More...

Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the distribution and emergency use of…
Read More...

Zymeworks Inc. announced that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in…
Read More...

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, which has the…
Read More...

Pfizer Inc. and BioNTech SE announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all…
Read More...

Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application for SB11, a proposed…
Read More...

InMed Pharmaceuticals Inc. a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development…
Read More...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the US Food and Drug…
Read More...